Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Vera Therapeutics (VERA – Research Report). The associated price target remains the same with $70.00.
Rami Katkhuda has given his Buy rating due to a combination of factors that highlight the potential of Vera Therapeutics’ atacicept in treating IgA nephropathy (IgAN). The recent completion of full enrollment in the Phase III ORIGIN 3 study, which evaluates the safety and efficacy of atacicept, is a significant milestone. The expected topline results from this study in the near term could support a Biologics License Application (BLA) submission for accelerated approval, positioning the company for a potential commercial launch in 2026.
Moreover, previous data from the Phase IIb ORIGIN study demonstrated positive long-term safety and efficacy outcomes, including stabilization of kidney function, which is promising for atacicept’s future. The treatment’s favorable administration profile and high retention rate further enhance its appeal. Despite competition in the IgAN landscape, the large commercial opportunity and the disease-modifying potential of atacicept support a positive outlook for the stock.
In another report released on March 26, Wells Fargo also maintained a Buy rating on the stock with a $70.00 price target.